Vagus Nerve Stimulation
Successful For Depression
December 16, 1999 - A nationwide clinical trial
has shown Vagus Nerve Stimulation
(VNS), an electrical stimulation therapy currently used to combat epilepsy,
to be a promising new method for treating patients with severe
treatment-resistant depression.
Results of the VNS pilot study showed that 40
percent of the treated patients displayed at least a 50 percent or greater
improvement in their condition, according to the Hamilton Rating Scale for
Depression, said Dr. A. John Rush, vice chairman for research in the Department
of Psychiatry at UT Southwestern Medical Center at Dallas and the study's lead
investigator. Half the patients also had at least a 50-percent improvement on
the Montgomery Asberg Depression Rating Scale. The condition of several
patients improved so substantially that they were able to return to work or
other normal activities. All the patients who responded to the treatment have
continued to do well.
Results of the 30-patient study were published
online in Biological Psychiatry in abstract form. Besides UT Southwestern, the
clinical study was conducted at Medical University of South Carolina College of
Medicine, Charleston; Columbia University College of Physicians and Surgeons
and the New York State Psychiatric Institute, New York; and Baylor College of
Medicine, Houston.
Approximately 18 million Americans
suffer from depression,
about 1 million of whom have
severe
treatment-resistant depression. "While the results are preliminary,
since the study included only 30 participants, they are extremely encouraging
and point toward the importance of conducting further research in this
treatment area," said Rush. He also said that test results indicate that
the treatment may have the potential to be used as an alternative to
electroconvulsive therapy
for some patients.
"For the first time in years, I can feel
joy, real joy," said Joanne Tesoriero, a Texas grandmother treated during
the pilot study and a lifelong sufferer of chronic depression. "VNS has
enabled me to do what years of drugs and even ECT has not. I can fully
appreciate my family, my children and my grandchildren. It is the best thing I
have ever done."
The Food and Drug Administration has approved
an expanded, 94-patient trial of VNS at up to 15 medical centers to begin next
year. Houston-based Cyberonics, which helped fund the research, developed the
treatment and devices. The firm has said that the study may ultimately involve
200 patients at up to 20 medical centers. The NCP System used to deliver VNS is
not currently approved for the treatment of depression.
"The vagus nerve carries information to
many areas of the brain that control mood, sleep and other functions,"
Rush said. VNS treatment involves stimulating the left vagus nerve in the neck
with a series of miniscule electrical pulses traveling through a small
surgically implanted wire attached to a pulse generator in the chest. The pulse
generator delivers stimulation to the vagus nerve in individualized therapeutic
"doses."
Study patients were required to be from 18-70
years of age and to be suffering from non-psychotic major depression or be in
the depressed phase of bipolar, or manic-depressive, illness. Participants'
current episodes had to have been more than two years in duration, or they had
to have suffered at least four different episodes. They also had to have failed
to respond to at least two medication trials in the current episode. Patients
who were currently taking psychotropic medications were allowed to continue on
their prescriptions.
Following surgery to implant the pulse
generator in the upper chest and tunnel the wires into the neck, where they
were wrapped around the left vagus nerve, patients received no electrical
stimulation while they healed, a two-week period for most.
"At the end of that time, the levels of
electrical impulses were adjusted for individual patient tolerance, this
process also taking two weeks," Rush said. Then the patients received VNS
for an eight-week period, each receiving his or her individually tolerated
dose.
Besides Rush, UT Southwestern researchers
included Dr. Mustafa Husain, associate professor of psychiatry; nurse Diane
Stegman in psychiatry; and Dr. Cole Giller, associate professor of neurological
surgery. Other authors included Dr. Harold Sackeim at Columbia; Dr. Mark George
at the Medical University of South Carolina; and Dr. Lauren Marangell at
Baylor.
top ~ more results from
various VNS clinical studies - 2
3 4
5
send page to a
friend
HealthyPlace.com
Depression Center Links
home ~ site map ~
causes ~ types ~
people ~
living with
treatments ~ self-help ~ support ~ suicide ~ related
issues
|